Kornimate/medical-research-clean huggingface dataset:
evaluation of a new imagingtechnologie for thrombosis

Conditions: Abdominal Aortic Aneurysm; Deep Vein Thrombosis

Summary: arterial and venous thrombi play an important role in various vascular diseases such as myocardial infarction, stroke, transient ischemic attacks (tia) and pulmonary embolism. these thromboembolic disorders are the leading causes of morbidity and mortality worldwide. a non-invasive method for the quantitative and effective detection of thrombi in the whole body has not yet been established. in spite of the available techniques, 30% to 40% of ischemic strokes "cryptogenic" (undetermined cause, the source of thromboembolism is never identified). possible causes of cryptogenic stroke atherosclerosis include in the aortic arch or intracranial arteries. a plaque in the arch or other large vessels could be an important source of cryptogenic strokes, however, are those difficult to detect by routine methods. the approach of thrombus targeted molecular imaging could identify potentially troublesome plaques early on before they become a dangerous rupture. the hypothesis is that the radiotracer 18f-arterial gp1 and venous thrombi using positron emission tomography (pet) can be made visible. the primary goal is the potential applicability of the substance as a pet tracer for diagnosing thrombi.

this is a first in man study with which we are testing the feasibility of the use of this radiopharmaceutical product to visualize a thrombus.

Eligibility criteria:
inclusion criteria: * patients with aaa (diameter \>3.5cm in duplex sonography) or acute dvt. * male and female patients 18 years and older, * signed informed consent after being informed exclusion criteria: * contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product, * women who are pregnant or breast feeding, * women with the intention to become pregnant during the course of the study, * other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease), * renal clearance \< 30 ml/min * known or suspected non-compliance, drug or alcohol abuse, * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the subject, * participation in another study with an investigational drug during the present study and 7 days thereafter. * enrolment of the investigator, his family members, employees and other dependent persons * last systemic treatment with gp iib/iiia antagonists should not have been applied within 48 h before performing study exam
albinterferon alfa 2b single dose in japanese chronic hepatitis c patients

Conditions: Chronic Hepatitis C

Summary: this study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of albinterferon alfa 2b (alb-ifn) single dose in japanese chronic hepatitis c patients


Eligibility criteria:
inclusion criteria: * have a clinical diagnosis of chc established on the basis of a detectable viral load as measured by a serum hcv rna test at least 6 months before and during the screening period. * age 20 to 69 years * have compensated liver disease results on screening laboratory assessment exclusion criteria: * evidence of decompensated liver disease and/or liver cirrhosis. * body weight \< 50 kg. * a history of immunologically mediated disease. * a history or other clinical evidence of interstitial lung disease

Keywords: chronic hepatitis c, albinterferon alfa 2b, phase i, japan
combating hospital-related function decline among prefrail older adults: a pilot study

Conditions: Frailty; Geriatrics

Summary: this study focuses on the "strength-based tailored-exercise program at home (step@home)" aimed at improving health outcomes for geriatric patients at risk of hospitalization-associated functional decline. it is a sequential mixed-method study that combines quantitative and qualitative approaches.

the research is a pilot study to develop the step@home intervention, integrating a strength-based, tailored exercise regimen for elderly patients post-hospital discharge. it addresses hospitalization-associated functional decline (hafd) by engaging patients in sustainable self-practice of physical exercises at home. the study employs empowerment strategies, lifestyle-integrated functional exercises, and optimized tele-platform use to maximize therapeutic benefits. by focusing on empowering patients through sustainable self-practice of physical exercises at home, it aims to enhance physical functions and improve health-related quality of life. the study also has significant real-world implications, potentially offering a scalable, effective solution for the broader geriatric population to manage hafd, thereby reducing healthcare costs and improving overall well-being. the research intends to assess the program's impact on physical functions and health-related quality of life, utilizing a sequential mixed-method approach for a comprehensive evaluation.

Eligibility criteria:
inclusion criteria: * i) aged 60 or above, ii) prefrail as defined by a score of 1-2 on the frail scale (fs) which measures fatigue, resistance, ambulation, illness and weight loss over the last 4 weeks, iii) discharged home without any community care referral, iv) cognitively capable to receive exercise training as indicated by an abbreviated mental test score of ≥ 6, and v) consented to participate exclusion criteria: * (i) engaging in moderate or vigorous exercise (\>60min/week) in the past 6 months, and (ii) with conditions contradictory to exercise training (e.g., acute muscular-skeletal problem, acute and unstable cardio-respiratory disease, etc).

Keywords: geriatric patients hospitalization-associated functional decline (hafd) frailty
pregabalin (lyrica) for the treatment of essential tremor

Conditions: Essential Tremor

Summary: this will be a multi-site, prospective, double-blind, randomized, placebo-controlled, crossover trial conducted over 6 months to assess the effectiveness and safety of pgb to treat symptoms of et.


Eligibility criteria:
inclusion criteria: 1. outpatients with essential tremor diagnosed by a movement disorder specialist. 2. age 18 years to 80 years. 3. postural tremor severity score of greater than or equal to 2 in the dominant hand/arm as measured by the ftm rating scale. 4. women of child-bearing potential must use a reliable method of contraception and must provide a negative pregnancy test at entry into the study. 5. baseline ekg read as within normal limits (no clinically significant abnormalities)obtained from primary care physician or cardiologist (performed within the past year). 6. serum creatine kinase, complete metabolic blood count, liver function tests, renal function tests, and platelets are within normal limits (blood drawn within the past year). 7. stable doses of all medications for 30 days prior to study entry and for the duration of the study. exclusion criteria: 1. any illness that in the investigator's opinion preclude participation in this study. 2. pregnancy or lactation. 3. concurrent participation in another clinical study. 4. dementia or other psychiatric illness that prevents the patient from giving informed consent (mini mental status exam score less than 24). 5. legal incapacity or limited legal capacity. 6. presence of severe renal disease (bun 50% greater than normal or creatine clearance \<60 ml/min) or hepatic disease. 7. presence of severe daytime sleepiness. 8. abnormal creatine kinase and/or platelet count in the past year. 9. present complaints of somnolence, dizziness, blurred vision, bleeding tendencies, cardiac abnormalities. 10. previous lack of response to other et therapies (propranolol and primidone). 11. patients who have had deep brain stimulation (dbs). 12. concomitant treatment with gabapentin.

Keywords: essential tremor tremor pregabalin lyrica
tech-assisted exercise training in chronic neck pain

Conditions: Chronic Neck Pain; Exercise Training Therapy

Summary: in this study, women with chronic neck pain residing in afyonkarahisar, turkey, will participate in an exercise-based intervention. both the control and experimental groups will engage in conventional exercise programs; however, the experimental group will also receive an additional technology-assisted exercise program. it is anticipated that these interventions will positively impact participants' daily living activities and functional abilities. the study aims to assess whether the inclusion of technology-supported exercises leads to superior outcomes compared to conventional exercises alone. the findings are expected to provide valuable evidence on the effectiveness of integrating technology-assisted exercise programs into physiotherapy and rehabilitation practices for women with chronic neck pain.

considering the complex nature of chronic pain, it is believed that integrating exercise approaches with technology may enhance the effectiveness of exercise programs, increase participation and its sustainability, support the continuity of overall health and functional outcomes, and have positive effects on behavior change. the light-based exercise set for measuring reaction time is frequently preferred in clinical settings. the device uses small, illuminated pods controlled by an application, providing visual cues that promote both physical and cognitive activity. the individual aims to deactivate the lit pods as quickly as possible. due to its interactive and enjoyable nature, it is commonly used across a wide range of populations-from pediatric to geriatric-especially among athletes. technology-focused approaches, compared to traditional exercise practices, are believed to positively influence patients' active participation in the treatment process through a more innovative and engaging experience.

Eligibility criteria:
inclusion criteria: * non-specific neck pain diagnosis * having neck pain persisting for at least 3 months * having the ability to speak and comprehend turkish fluently * a pain score of 3 or higher according to the numerical rating scale * a score of 5 or higher on the neck disability index exclusion criteria: * having a history of spinal surgery. * having an additional musculoskeletal disorder affecting the cervical region and upper extremities (e.g., scoliosis, rheumatoid arthritis, fibromyalgia, etc.). * receiving physical therapy and/or other treatments for any reason within the last 6 months. * having a diagnosed psychiatric disorder. * having a vestibular pathology. * having visual problems despite using visual aids. * being pregnant. * having a neurological deficit that may affect balance. * discontinuing or being unable to complete the treatment process.
study of inflammatory and physiological profiles of healthy and diseased lung

Conditions: COPD; Asthma; Airway Disease

Summary: there are over 700,000 uk hospital admissions every year with lung disease symptoms. two of the most common lung diseases contributing to these numbers are asthma and chronic obstructive pulmonary disease (copd). the immunopathology of these diseases is not fully understood. matched samples from the respiratory tract and circulation will be used to identify immune patterns throughout the respiratory system to elucidate the immunopathology of airway disease.

in this observational study, we will be enrolling patients with diagnosed or suspected airways disease who are over 18 years old, as well as age matched healthy volunteers with no significant illness. participants will be asked if they consent to enter the study, invited at clinically relevant time points (treatment change, disease exacerbation etc.) and to optional bronchoscopy visits. it is expected that participants will be seen yearly with any additional exacerbation/treatment visits also recorded. research visits will occur at king's college london and the guys and st thomas' nhs foundation trust (gstft), with all bronchoscopy visits occurring within gstft 1. disease specific questionnaires. 2. lung function tests including spirometry or oscillometry (if not performed previously within 6 months) 3. sputum collection 4. nasal sampling including nasosorption, nasal brushing, nasal lavage, or nasopharyngeal swabs 5. exhaled breath 6. blood samples (\<6 tablespoons) optional 7. bronchoscopy involving a flexible fibreoptic camera passed into the lungs to collect bronchoalveolar lavage, bronchosorption, bronchial brushings and bronchial biopsies. 8. to repeat these procedures at later time - expected once per year or at times of clinically relevant changes

Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study * aged 18 years or above * patient: known or suspected airway disease * healthy volunteer: considered to be in good health with no significant comorbidity (immune disorder, cancer etc.) exclusion criteria: * known or suspected current pulmonary tuberculosis, hiv (human immunodeficiency virus), hepatitis b virus, hepatitis c virus. * surgery within the preceding 6 weeks * participants who are pregnant * history of psychiatric, medical, or surgical disorders that in the opinion of the chief investigator may interfere with sample collection, undergo a bronchoscopy, or may compromise study completion or data collection * alcohol or recreational drug abuse * diagnosis of immunodeficiency requiring treatment * unable to provide written informed consent * unable to read or write english * be considered, in the opinion of the investigator, to be an unsuitable candidate for the study

Keywords: airway disease pulmonary disease
food as medicine study

Conditions: Diabetes Mellitus, Type 2

Summary: the investigators are conducting a pre-randomized controlled trial to assess the effect of a 6 month produce prescription intervention for patients enrolled in medicaid who experience consistently uncontrolled hemoglobin a1c (hba1c). the study is conducted at kaiser permanente southern california, a large and diverse integrated health care system that serves 4.7 million members. eligible participants are members aged 18 or older, currently enrolled in medicaid who were diagnosed with diabetes for at least 24 months and had at least two hba1c measurements of 7.5% or higher in the past 12 months. patients in the intervention arm may enroll in tele nutrition counseling. the study team will recruit a total of 450. participants, will be pre-randomized into one of three arms, 1) high dose intervention arm, a 2) low dose intervention and 3) a usual care group to achieve 150 participants enrolled in each arm. produce is delivered weekly for participants of both intervention arms. participants randomized to the high dose arm will receive a greater amount per month of produce versus the low dose amount (for a family of 3-4, $180 per month versus $135 respectively). foods are provided along with recipes. the amount of food delivered is adjusted for each additional family member for up to 5 family members. the primary outcome is change in hemoglobin a1c pre-intervention and 6 months after enrollment. secondary outcomes include, food insecurity status, dietary intake and other patient reported outcomes related to barriers to healthy eating including family conflict and cooking habits.


Eligibility criteria:
inclusion criteria: * age 18 years of age or older * diagnosed with type 2 diabetes for at least 24 months * diagnosed with type 2 diabetes and have at least two hba1cs of 7.5% or higher in 12 months prior to recruitment * have medicaid insurance at the time of their last hba1c test * will be able to provide informed consent * will be able to consent to research activities, including receiving a weekly produce box * will be able to receive and prepare delivered foods exclusion criteria: * pregnant women * living in a board and care where your meals are provided for you * unable to provide informed consent
sulindac and epirubicin in treating patients with metastatic malignant melanoma

Conditions: Melanoma (Skin)

Summary: rationale: sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. giving sulindac together with epirubicin may kill more tumor cells. purpose: this phase ii trial is studying how well giving sulindac together with epirubicin works in treating patients with metastatic malignant melanoma.

objectives: primary * to estimate the non-comparative efficacy of sulindac and epirubicin hydrochloride in patients with metastatic malignant melanoma. secondary * to characterize the toxicity of this regimen in these patients. outline: this is a multicenter study. patients receive oral sulindac 2 hours prior to receiving epirubicin hydrochloride iv over 15 minutes on day 1. treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. previously collected tumor blocks are assessed for cancer resistance markers by ihc. after completion of study treatment, patients are followed for 1 month, and then every 3 months thereafter.

Eligibility criteria:
disease characteristics: * histologically confirmed malignant melanoma * metastatic disease * tumor block available for resistance marker analysis * measurable or evaluable disease * no active brain metastases except for patients who have undergone successful complete excision of solitary brain metastasis patient characteristics: * karnofsky performance status 80-100% * anc \> 1 x 10\^9/l * platelet count \> 100 x 10\^9/l * hemoglobin \> 9 g/dl * serum bilirubin normal (except in patients with benign congenital hyperbilirubinemia) * not pregnant or nursing * negative pregnancy test * normal cardiac ejection fraction, cardiac wall motion, and ecg * no active heart disease, including any of the following: * myocardial infarction within the past year * pericarditis * existing hypertension requiring treatment * no other active serious medical or psychiatric disease * no prior or concurrent malignancy, other than basal cell carcinoma of the skin , or carcinoma in-situ of the cervix prior concurrent therapy: * no prior anthracycline or anthracenedione-containing chemotherapy regimen * no prior cardiac radiotherapy * no major surgery within the past 2 weeks * no participation in any clinical trial within the past 4 weeks * no other concurrent anticancer therapies * concurrent bisphosphonates allowed in patients with bony metastases with extra-osseous measurable or evaluable lesions * no other concurrent experimental medications

Keywords: stage iv melanoma
treating stimulant addiction with repetitive transcranial magnetic stimulation

Conditions: Stimulant Use Disorder; Substance-related Disorders

Summary: the purpose of this study is to establish a new treatment (repetitive transcranial stimulation (rtms)) for veterans with stimulant use disorder (sud). despite the large public health burden imposed by sud, there is currently no fda-approved or widely recognized effective somatic treatment. rtms may be a promising treatment option for sud. in this study, we will demonstrate the feasibility of applying rtms to veterans with sud, examine the efficacy of rtms in the treatment of sud, and explore biomarkers that may guide patient selection for rtms treatment and predict treatment response.


Eligibility criteria:
inclusion criteria: * structured clinical interview for dsm disorders (scid) confirmed diagnosis of sud, severe * last use of stimulants \>1 and \<6 weeks * stable medication regimen (no change in dose or agents between 2 weeks prior to the start of and throughout the treatment phase of the study) * stable social environment and housing to enable regular attendance at clinic visits. * ability to undergo cognitive testing, functional magnetic resonance imaging (fmri) scans, and rtms (no contraindications) * intelligence quotient (iq) \> 80 * stable medical health * veteran at palo alto va's addiction treatment services exclusion criteria: * pregnant or lactating female * history of prior adverse reaction to tms * on medications thought to significantly lower seizure threshold, e.g.: * clozapine * chlorpromazine * clomipramine * bupropion \> 400 mg/day * use of direct dopaminergic antagonists or agonists * history of seizures or conditions known to substantially increase risk for seizures * implants or medical devices incompatible with tms * acute or unstable chronic medical illness that would affect participation or compliance with study procedures, e.g. unstable angina * unstable psychiatric symptoms that precludes consistent participation in the study, e.g.: * active current suicidal intent or plan * severe psychosis * inability to undergo fmri scan, e.g. claustrophobia, presence of ferromagnetic objects in subject's body * other substance use disorder not in sustained remission * chronic or recurring axis i psychiatric condition preceding sud other than ptsd

Keywords: magnetic resonance imaging transcranial magnetic stimulation dopamine reward processing